RecruitingPhase 2NCT07761910

Prospective Study on Radiation Induced Cardiotoxicity Assessed By PET-CT for Locally Advanced Non-Small Cell Lung Cancer (NSCLC)

Prospective clinical study designed to evaluate damage to the heart after receiving standard of care chemotherapy and radiation therapy for locally advanced Non-Small Cell Lung Cancer (NSCLC).

Checked against the public recordLast updated Aug 12, 2026 · Source: ClinicalTrials.gov

StatusRecruiting
PhasePhase 2
U.S. locations1
SponsorIndiana University
01
Study overview

What this study is about

Purpose
Diagnostic
Study type
Interventional
Phase
Phase 2
Sponsor
Indiana University
Interventions being studied
Diagnostic Test: PET/CT 18F-Flurpiridaz Rest/Stress Test; Device: Coronary CT Angiography (CCTA); Drug: 18F-Flurpiridaz
02
Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

03
Public criteria

Who may be able to participate

Inclusion Criteria: 1. Age ≥ 18 at time of consent 2. Ability to provide written informed consent and HIPAA authorization 3. Stage III NSCLC per AJCC 8th edition guideline, confirmed by pathological diagnosis and PET/CT. 4. To receive standard definitive concurrent chemoradiation therapy per NCCN guidelines. 5. Tumor estimated to be within 2cm of heart contour or anticipated MHD\>10Gy per treating physician. Exclusion Criteria: 1. Patients treated with stereotactic body radiotherapy (SBRT). 2. Prior thoracic radiotherapy. Exclusion for Coronary computed tomography angiography (CCTA) 1. History of a severe anaphylactic reaction to iodinated contrast. 2. Renal insufficiency (defined as estimated CrCl less than 30 mL/min). 3. Inability to hold breath for more than 5 seconds. 4. Patients on radioactive iodine therapy. Exclusion for 18F-Flurpiridaz PET/CT Test 1. Second-degree AV block, third-degree AV block, and sinus node disease (such as sick sinus syndrome or symptomatic bradycardia) without a functioning pacemaker. Note: Resting 12-lead EKG will be ordered at the time of enrollment to be performed prior to PET/CT stress test. 2. Patients with bronchospastic diseases including asthma and chronic obstructive pulmonary disease (COPD) who have an acute exacerbation or active wheezing (a high-pitched, musical, adventitious lung sound produced by airflow through the narrowed airways) on the day of PET CT exam. 3. Patients who are hypotensive (systolic blood pressure less than 90 mm Hg) on the day of the PET/CT scan.

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

04
Study sites

U.S. locations

  • Indiana University Melvin and Bren Simon Comprehensive Cancer CenterIndianapolis, Indiana

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Aug 12, 2026. Always confirm current availability with the study team.

View original record ↗